121 related articles for article (PubMed ID: 37936466)
1. Research on the Inhibitory Effect of Doxorubicin-loaded Liposomes Targeting GFAP for Glioma Cells.
Li Q; Xu J
Anticancer Agents Med Chem; 2024; 24(3):177-184. PubMed ID: 37936466
[TBL] [Abstract][Full Text] [Related]
2. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.
Lin Q; Mao KL; Tian FR; Yang JJ; Chen PP; Xu J; Fan ZL; Zhao YP; Li WF; Zheng L; Zhao YZ; Lu CT
Cancer Chemother Pharmacol; 2016 Feb; 77(2):269-80. PubMed ID: 26666650
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
5. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
[TBL] [Abstract][Full Text] [Related]
6. Cell-Penetrating Peptide and Transferrin Co-Modified Liposomes for Targeted Therapy of Glioma.
Wang X; Zhao Y; Dong S; Lee RJ; Yang D; Zhang H; Teng L
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574945
[TBL] [Abstract][Full Text] [Related]
7. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice.
Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W
Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637
[TBL] [Abstract][Full Text] [Related]
8. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
[TBL] [Abstract][Full Text] [Related]
9. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
11. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
12. A stabilized peptide ligand for multifunctional glioma targeted drug delivery.
Ying M; Shen Q; Zhan C; Wei X; Gao J; Xie C; Yao B; Lu W
J Control Release; 2016 Dec; 243():86-98. PubMed ID: 27693752
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-Loaded Liposome with the Function of "Killing Two Birds with One Stone" against Glioma.
Cen J; Dai X; Zhao H; Li X; Hu X; Wu J; Duan S
ACS Appl Mater Interfaces; 2023 Oct; 15(40):46697-46709. PubMed ID: 37782688
[TBL] [Abstract][Full Text] [Related]
14. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes.
Gao JQ; Lv Q; Li LM; Tang XJ; Li FZ; Hu YL; Han M
Biomaterials; 2013 Jul; 34(22):5628-39. PubMed ID: 23628475
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics.
Thakur A; Sidu RK; Zou H; Alam MK; Yang M; Lee Y
Int J Nanomedicine; 2020; 15():8331-8343. PubMed ID: 33149579
[TBL] [Abstract][Full Text] [Related]
16. Environmentally Self-Adaptative Nanocarriers Suppress Glioma Proliferation and Stemness via Codelivery of shCD163 and Doxorubicin.
Liu J; Zhang Y; Chen T; Chen H; He H; Jin T; Wang J; Ke Y
ACS Appl Mater Interfaces; 2020 Nov; 12(47):52354-52369. PubMed ID: 33196179
[TBL] [Abstract][Full Text] [Related]
17. Glioma targeted delivery strategy of doxorubicin-loaded liposomes by dual-ligand modification.
Han W; Yin G; Pu X; Chen X; Liao X; Huang Z
J Biomater Sci Polym Ed; 2017 Oct; 28(15):1695-1712. PubMed ID: 28699828
[TBL] [Abstract][Full Text] [Related]
18. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
Xiao P; Zhao J; Huang Y; Jin R; Tang Z; Wang P; Song X; Zhu H; Yang Z; Yu N
Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
[TBL] [Abstract][Full Text] [Related]
19. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]